## State and Public School Life And Health Insurance Board Minutes February 8, 2011

The 113th meeting of the State and Public School Life and Health Insurance Board (hereinafter called the Board), met on February 8, 2011 at 1:00 p.m. in the EBD Board Room, 501 Woodlane, Suite 500, Little Rock, AR 72201.

#### MEMBERS PRESENT

Janis Harrison Lloyd Black William Goff Shelby McCook Renee Mallory Dr. Andrew Kumpuris Bob Alexander

#### **MEMBERS ABSENT**

Dr. Joseph Thompson Robert Watson Vance Strange John Kirtley

Jason Lee, Executive Director, Employee Benefits Division.

#### OTHERS PRESENT:

George Platt, Leigh Ann Chrouch, Doug Shackelford, Stella Greene, Amy Tustison, Marla Wallace; Paige Harrington, Latryce Taylor, Pamela Lawrence, Lori Eden, Sherry Bryant, Sherri Saxby, Tracy Collins, Michael Stewart, Cathy Harris, EBD; Rhonda Hill, EBD-ACHI; Barbara Melugin, Ron Deberry, David Bridges, Kathy Ryan, ABCBS/Health Advantage; Sarah Sanders, Wayne Whitley, AR Highway & Transportation Dept, Shonda Rocke, Informed Rx; Frances Brown, Bryan Meldrum, NovaSys; Jill Johnson, UAMS-College of Pharmacy; Marc Watts, AR State Employee Association; Sean Seago, Merck; Steve Singleton, ARTA; Kristi Clark, ABA; Treg long, ACR; Sharon Marcum, LifeSynch;

#### **CALL TO ORDER**

Meeting was called to order by Janis Harrison, Chairman.

#### **APPROVAL OF MINUTES**

The request was made by Harrison to approve the October 12, 2010 minutes. Mallory made the motion to approve minutes. Alexander seconded. All were in favor. Minutes approved.

#### FINANCIALS by Leigh Ann Chrouch, CFO

Chrouch presented detailed financial statements for the Arkansas State Employees (ASE) and the Public School Employees (PSE) and the penalties assessed by state agencies and school districts for September 2010 through December 2010.

McCook requested that information for behavioral health be included in the financials.

**DRUG UTILIZATON & EVALUATION COMMITTEE** by Dr. William Golden Dr. Golden reported the DUEC met on February 7, 2011. Golden presented the following recommendation for the Board's consideration.

**1. MAXALT -** Generic Name: rizatriptan (RYE za TRIP tan) is used to treat migraine headaches.

Dr. Golden informed the Board the packaging for Maxalt has changed from 12 tablets to 18 tablets per package. The current Policy is 12 tablets per 31 days.

**Recommendation** – Allow for 18 tablets per 45 days. The DUEC committee agreed to allow EBD to manage the prescription and co-pay adjustments and to inform the committee if needed.

McCook made the motion to accept the recommendation for Maxalt tablets. Mallory seconded. All were in favor. Motion carried.

#### 2. FIRST REVIEW MEDICATIONS - NEW DRUGS Oct-Dec 2010

**GILENYA CAP 0.5MG** (fingolimod) is the first oral therapy approved for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

**Recommendation:** Tier 3 status (specialty drug) with prior authorization

McCook made the motion for GILENYA CAP 0.5MG to be placed on the Tier 3 status with prior authorization. Black seconded. All were in favor. Motion carried.

**PRADAXA CAP 75, 150MG** is FDA-approved for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

**Recommendation:** Tier 3 status with prior authorization and a quantity limit of 2 tablets a day per 31 days.

McCook made the motion to place PRADAXA CAP 75, 150MG on tier 2 with prior authorization and a quantity limit of 2 tablets a day per 31 days. Black seconded. All were in favor. Motion carried.

#### 3. REVIEW OF NEWER DIABETES DRUGS FOR TYPE 2 DIABETES

Dr. Golden provided the Board with a report on the plan cost and member utilization for Diabetes drugs in 2010.

**a.** TZD's-Thiazolidinediones (Rosiglitazone, Pioglitazone), (Avandia, Avandaryl, Avandamet, Actos, ActoplusMet)

**Recommendation**: Restrict the access to Rosiglitazone. Stop covering rosiglitazone (Avandia, Avandamet and Avandaryl) effective July 1, 2011. No Pioglitazone (Actos) without metformin (at a near maximum daily dose-1000mg daily) or a contraindication to metformin.

McCook made the motion to delay the decision until next month. The DUEC will re-present their recommendation for TZD's with step therapy criteria.

**b.** Exenatide (Byetta), Liraglutide (Victoza) and Sitagliptin (Janumet) Saxagliptin, (Onglyza, Kombiglyze XR)

**Recommendation:** Option 1 – Discontinue covering Exenatide (Byetta), Liraglutide (Victoza) based on lack of outcomes evidence. Option 2- Deny if any insulin claim in past 30 days. Continue no monotherapy access for exenatide or liraglutide. PA all prescription. Criteria requires a current metformin fill for 90 of the past 120 days goal A1c, and then require inpatients who cannot tolerate metformin, the use of a sulfonylurea or the use of pioglitazone, unless contraindicated due to HF, edema, or fracture risk.

Recommendation: Option 1- Discontinue covering Sitagliptin (Janumet) Saxagliptin, (Onglyza, Kombiglyze XR) based on lack of outcomes evidence. Option 2- Deny if any insulin claim in past 30 days. Continue no monotherapy access for sitagliptin or saxagliptin. PA all prescription, criteria requires a current metformin fill for 90 days of the past 120 days at the maximum or near maximum dose failure to reach goal A1C, and require the use of concomitant sulfonylurea and/or pioglitazone in patients who have not reached their HbA1C goal with metformin monotherapy, unless contraindicated due to HF, edema or fracture risk

The Board was interested in option 2 for Exenatide (Byetta), Liraglutide (Victoza) and Sitagliptin (Janumet) Saxagliptin, (Onglyza, Kombiglyze XR). The Board decline to make a decision until the DUEC return with a viable mechanism on how to implement option 2.

c. Pramlintide (Symlin, SymlinPen)Recommendation: Exclude

McCook made the motion that the DUEC develop a step therapy for Pramlintide (Symlin, SymlinPen) before the Board entertain the recommendation to exclude. Alexander seconded. All were in favor. Motion carried.

#### BENEFITS SUBCOMMITTEE REPORT by Lloyd Black, Co-Chairman

Black reported the Benefits Subcommittee met on January 14, 2011. EBD's Director provided the committee with an overview of the 2010 PSE plan year and also side by side comparison report of the current health plan arrangement for ARHealth active employees and Medicare primary members vs. the Medicare Advantage plan.

Lee provided an overview of the 2010 PSE Plan year review for the Board. Lee said he will present the ASE plan year review in the next meeting.

Black reported the Benefits committee discussed Medicare Advantage as a possible option for the ARHealth Medicare Retiree population, and then they requested further in depth investigation by the BSPW in conjunction with the plan's actuarial firm; to look into financial data on plan's current performance compared to Medicare Advantage Plan without restriction; and evaluate the same advantages of an employer group waiver plan.

Alexander made the motion to accept the Benefits Sub-committee report. McCook seconded. All were in favor. Motion carried.

### **DIRECTOR'S REPORT** by Jason Lee

Lee explained that every year the Board is required to review and adopt the approval of reimbursement of expenses and stipend.

Effective January 1, 2011 and in accordance with ACA §25-16-902, the State and Public School Life and Health Insurance Board ("Board") hereby approves the reimbursement of qualified expenses at the rate established for state employees by state travel regulations with the following limitation regarding non-board meetings.

 Any meeting or conference attended by any member of the Board must be at the request of the Board Chair or the Executive Director.

McCook made the motion to adopt. Black seconded. All were in favor. Motion carried.

Effective January 1, 2011 and in accordance with ACA § 25-16-903, the State and Public Life and Health Insurance Board ("Board") hereby approves the stipend amount of \$60.

McCook made the motion to adopt the stipend amount of \$60. Black seconded. All were in favor. Motion carried.

Lee referenced the financials for the catastrophic reserve amount. Lee explained they have received the December claims and have reassessed that number as per the methodology adopted by the Board; 50% of the average claims for medical and pharmacy for July through December. Lee informed the Board that effective January 1, 2011 the catastrophic reserve amount for ASE will be 8,900.000 and 9,000.000 for PSE.

McCook made the motion to apply the methodology and approve the amount. Black seconded. All were in favor. Motion carried.

Lee provided the Board with a legislative update of the 88th General Assembly - Regular Session 2011.

**SB66-** Requires Health Plan to an act to require health benefit plans to provide coverage for the treatment of morbid obesity.

Alexander made the motion for EBD's Director to obtain a legal opinion from the plan's consultants, and then depending on the findings; obtain a legal opinion from the Attorney General's Office. McCook seconded. All were in favor. Motion carried.

**HB1315** – will require Health Plans to provide health coverage for autism spectrum disorders. Lee informed the Board that Cheiron has reported utilization will be \$5M per year in claims experience.

Alexander suggested the Board send EBD's Director to speak against the bill because of the cost impact to the plan.

McCook made the motion to obtain Cheiron's advice and projections on HB1315 and for EBD's Director to provide the information at the HB Committee meeting.

Meeting Adjourned.

## **AGENDA**

### State and Public School Life and Health Insurance Board

## EBD Board Room - 501 Building - 5<sup>th</sup> Floor

February 8, 2011 1:00 p.m.

1.	Call to Order	Janis Harrison, Chair
2.	Approval of Minutes	Janis Harrison, Chair
3.	Financials	Leigh Ann Chrouch, Chief Fiscal Officer
4.	Sub-Committee Report a. Benefits Sub-Committee b. DUEC Report	
5.	Director's Report	Jason Lee, Executive Director

Next Meeting March 8, 2011

Arkansas State Emp	oloyees (ASE) Financial				30,	
	ARHealth	Health Adv	No	vaSys		Total
Actives		25,132		1,225		26,35
Actives HD				953		95
letirees etirees	8,850					8,85
COBRA		132		6		13
Total Total	8,850	25,264		2,184		36,29
Operations as of 09/30/10						
				Current		Year to Date
<u>unding</u>				Month		(9 months)
tate Contribution			\$	13,649,350	\$	122,472,97
Employee Contribution, Rebate	es, Life		\$	7,703,266	\$	72,027,40
Medicare Subsidy			\$	384,708	\$	3,161,71
Total Funding			\$	21,737,324	\$	197,662,10
<u>xpenses</u>						
Medical Expenses						
Claims Expense			\$	15,421,627	\$	119,972,93
Claims IBNR			\$	-	\$	2,570,00
Medical Admin Fees			\$	882,320	\$	7,951,28
Refunds			\$	6,001	\$	21,64
Behavioral Health			\$	0,001		2,275,59
				70.010	\$	
ife Insurance			\$	79,010	\$	714,87
Pharmacy Expenses			_			
RX Claims			\$	5,383,813	\$	43,172,48
RX IBNR			\$	-	\$	180,00
RX Admin			\$	74,445	\$	606,21
Plan Administration			\$	148,639	\$	1,927,64
Total Expenses			\$	21,995,857	\$	179,392,68
Net Income/(Loss)			\$	(258,532)	\$	18,269,41
Balance Sheet as of 09/30/1	0					
<u>Assets</u>						
Bank Account					\$	18,472,34
State Treasury					\$	83,282,96
Receivable from Cafeteria Plar	١				\$	8,767,65
Receivable from PSE					\$	-
Receivable from Provider					\$	1,075,85
Receivable from Medicare					\$	384,70
Accounts Receivable					\$	75,45
Total Assets				•	\$	112,058,98
				:		
<u>iabilities</u>						
Accounts Payable					\$	4,133,18
Deferred Revenues					\$	4,174,37
Due to Cafeteria					\$	-
Due to PSE					\$	-
lealth IBNR					\$	21,570,00
RX IBNR					\$	2,680,00
Total Liabilities					\$	32,557,55
Net Assets				•	\$	79,501,42
					7	/00 . / 1.
ess Reserves Allocated:					Φ.	(0.100.0)
0 1 1 1: 5					a.	
Catastrophic Reserve					Þ	•
Catastrophic Reserve Pharmacy Reward Program (2 Net Assets Available	2010-\$1,500,000)				\$ \$	(8,100,00 (1,500,00 69,901,42

ASE Cafeteria Plan Financials 2010- January 1, 20	10 through S	Septembe	er 30, 2010
Cafeteria Plan Operations as of 09/30/10			
<u>Funding</u>		Current Month	Year to Date (9 months)
FICA Savings Interest, Penalties, Tax Set Off <b>Total Funding</b>	\$ \$ \$	321,418 4,205 325,623	\$ 3,209,059 \$ 78,022 \$ 3,287,081
<u>Expenses</u>			
Plan Administration Forfeited Benefits (Annual Expense) FICA Savings Transfer (Annual Expense) Total Expenses	\$ \$ \$	840 - - 840	\$ 114,119 \$ 6,297,637 \$ - \$ 6,411,757
Net Income/(Loss)	\$	324,783	\$ (3,124,676)
Balance Sheet as of 09/30/10			
Assets State Cafeteria (Flexible Benefits) Admin Acct (FICA Savings) State Treasury Due from Health Plan Due from State Employee Fund Accounts Receivable Total Assets			\$ 822,911 \$ 578,202 \$ 8,733,132 \$ - \$ - \$ 13,400 \$ 10,147,646
Liabilities Accounts Payable Due to Health Plan (FICA Savings Annual) Due to Health Plan (Forfeited Benefits Annual) Total Liabilities			\$ 193,101 \$ 7 \$ 8,767,649 \$ 8,960,758
Net Assets			\$ 1,186,888

Public Sch	nool Employees (PSE	) Financials - October 1	, 2009 throu	gh Septemb	er 3	0, 2010
	ARHealth	Health Adv	Nove	aSys		Total
Actives		36,202		3,551		39,753
Actives HD				2,476		2,476
Retirees	7,654					7,654
COBRA		1,127		120		1,247
Total	7,654	37,329		6,147		51,130
Operations as of 0	9/30/10				_	
				Current		Year to Date
<u>Funding</u>				Month		(12 months)
District Contribution			\$	5,527,414	\$	68,656,707
Employee Contributi			\$	12,564,766	\$	148,661,729
Dept of Ed \$35,000,0	00 & \$15,000,000		\$	3,181,818	\$	50,000,000
Total Funding			\$	21,273,998	\$	267,318,436
<u>Expenses</u>						
Medical Expenses:						
Claims Expense			\$	17,625,213	\$	192,676,021
Claims IBNR			\$	_	\$	3,250,000
Medical Admin Fees			\$	1,264,030	\$	15,437,040
Refunds			\$	9,623	\$	(14,206)
Behavioral Health			\$		\$	3,411,510
Pharmacy Expenses:			Ψ		Ψ.	5, , 5 . 0
RX Claims			\$	4,609,075	\$	49,683,757
RX IBNR			\$	-	\$	90,000
RX Admin			\$	64,623	\$	743,295
Plan Administration			\$	185,442	\$	3,502,252
Total Expenses			\$	23,758,007	\$	268,779,668
-						
Net Income/(Loss)			\$	(2,484,009)	\$	(1,461,233)
Reserve Activity:	- Duanai was fan Diaw Va	10/01/00 00/00/10	¢.	1////0	Φ.	0.000.000
	e Premiums for Plan Yr		\$	166,663	\$	2,000,000
	or Plan Year 01/01/10-1	2/31/10	\$	383,402	\$	3,450,617
Net Income/(Loss) A	mer keserves		\$	(1,933,944)	\$	3,989,385
Balance Sheet as	of 09/30/10					
<u>Assets</u> Bank Account					¢	15,113,031
					\$	
State Treasury	i.al.a.r				\$	57,737,138
Receivable from Pro					\$	1,009,046
Accounts Receivable	е				φ	415,755
Due from ASE  Total Assets					\$	74,274,969
IOIUI Asseis					Ψ	/4,2/4,707
<u>Liabilities</u>					•	
Accounts Payable					\$	4,044,837
Due to ASE					\$	-
Deferred Revenues					\$	1,466,641
Health IBNR					\$	25,500,000
RX IBNR					\$	2,340,000
Total Liabilities					\$	33,351,479
Net Assets					\$	40,923,491
Retiree Premiums for Active Premiums for Retiree Premiums for Active Premiums for Retiree Premiums for Catastrophic Reser	r Plan Year 10/01/09-0 or Plan Year 01/01/10-1 r Plan Year 10/01/10-1: or Plan Year 01/01/11-1 r Plan Years 1/01/12-12 or Plan Years 01/01/12- ve	2/31/10 (\$4,000,000 + \$600 2/31/11 (\$11,840,000) 2/31/11 (\$760,000) 2/31/13 (\$7,344,000 + \$3,29 12/31/13 (\$456,000 + \$304,	6,000 = \$10,64	10,000)	\$ \$ \$ \$ \$ \$ \$ \$	(1,150,206) (11,840,000) (760,000) (10,640,000) (760,000) (9,100,000)
	Program (2010-\$1,500,	000)			<u> </u>	(1,500,000)
Net Assets Available	•				\$	5,173,285

Arkansas siaie Em	oloyees (ASE) Financio	Health Adv		/aSys	· , <u>~</u> \	Total
Actives	Akhediin	25,099	NOV	1,215		26,31
Actives HD		25,077		948		94
etirees	8,876			740		8,87
COBRA	8,076	133		7		14
otal	8,876	25,232		2,170		36,27
Operations as of 10/31/10	0,07 0	25,252		2,170		30,27
operations as or 10/31/10				Current		Year to Date
unding				Month		(10 months)
tate Contribution			\$	13,648,626	\$	136,121,60
Employee Contribution, Rebates	Life		•	7,191,610	φ \$	79,219,02
	, 110		\$	7,171,010	φ φ	
Medicare Subsidy			\$		φ	3,161,71
Total Funding			<u> </u>	20,840,236	\$	218,502,33
<u>xpenses</u>						
Medical Expenses						
Claims Expense			\$	12,729,201	\$	132,702,13
Claims IBNR			\$	-	\$	2,570,00
Medical Admin Fees			\$	880,872	\$	8,832,15
Refunds			\$	(3,128)		18,51
Behavioral Health			\$	566,751	\$	2,842,34
ife Insurance			\$	79,036	\$	793,91
Pharmacy Expenses			*	,	т.	
RX Claims			\$	5,180,234	\$	48,352,72
RX IBNR				-	\$	180,00
RX Admin			\$ \$ \$	71,920	\$	678,13
Plan Administration			Ψ \$	231,761	\$	2,159,40
Total Expenses			\$	19,736,648	\$	199,129,33
Net Income/(Loss)			\$		\$	19,373,00
ver income/(Loss)			φ	1,100,000	φ	17,373,00
Balance Sheet as of 10/31/10						
<u>Assets</u>						
Bank Account					\$	10,800,80
State Treasury					\$	88,283,48
Receivable from Cafeteria Plan					\$	8,767,67
Receivable from PSE					\$	_
Receivable from Provider					\$	539,71
Receivable from Medicare					\$	-
Accounts Receivable					\$	640,20
Total Assets				•	\$	109,031,88
! l. 1111				:	•	
<u>liabilities</u>					¢	1.05
Accounts Payable					<b>\$</b>	1,25
Deferred Revenues					<b>\$</b>	4,175,61
Due to Cafeteria					<b>\$</b>	-
Due to PSE					<b>\$</b>	-
Health IBNR					<b>\$</b>	21,570,00
RX IBNR <b>Total Liabilities</b>					\$	2,680,00 28,426,87
				:	\$	80,605,01
Jet Assets					a)	
Net Assets					т.	00,000,0
ess Reserves Allocated:					\$	
Net Assets  Less Reserves Allocated:  Catastrophic Reserve  Pharmacy Reward Program (20	10-\$1 500 0001				\$	(8,100,00

ASE Cafeteria Plan Financials 2010- January 1, 2	010 through	October	31, 2010
Cafeteria Plan Operations as of 10/31/10			
<u>Funding</u>		Current Month	Year to Date (10 months)
FICA Savings Interest, Penalties, Tax Set Off <b>Total Funding</b>	\$ \$ \$	357,448 433 357,881	\$ 3,566,507 \$ 78,455 \$ 3,644,962
<u>Expenses</u>			
Plan Administration Forfeited Benefits (Annual Expense) FICA Savings Transfer (Annual Expense)  Total Expenses	\$ \$ \$	26,067 - - 26,067	\$ 140,187 \$ 6,297,637 \$ - \$ 6,437,824
Net Income/(Loss)	\$	331,814	\$ (2,792,862)
Balance Sheet as of 10/31/10			
Assets State Cafeteria (Flexible Benefits) Admin Acct (FICA Savings) State Treasury Due from Health Plan Due from State Employee Fund Accounts Receivable Total Assets			\$ 899,317 \$ 9,643,761 \$ - \$ - \$ - \$ 13,498 \$ 10,556,577
Liabilities Accounts Payable Due to Health Plan (FICA Savings Annual) Due to Health Plan (Forfeited Benefits Annual) Total Liabilities			\$ 270,198 \$ 28 \$ 8,767,649 \$ 9,037,875
Net Assets			\$ 1,518,701

Public S	School Employees (P:	SE) Financials - October	1, 2010 thro	ugh Octobe	er 31	, 2010
	ARHealth	Health Adv	Nov	aSys		Total
Actives		37,409		4,547		41,956
Actives HD				2,977		2,977
Retirees	7,688					7,688
COBRA		1,147		126		1,273
Total	7,688	38,556		7,650		53,894
Operations as of		337333		.,		22,51
Operations as or	10/31/10			Current		Year to Date
F				Month		
<u>Funding</u>						(1 month)
District Contribution			\$	5,889,236	\$	5,889,236
Employee Contribu			\$	13,144,391	\$	13,144,391
Dept of Ed \$35,000	,000 & \$15,000,000		\$	6,931,818	\$	6,931,818
Total Funding			\$	25,965,445	\$	25,965,445
F						
Expenses						
Medical Expenses:			•	1 4 0 4 1 00 7		1 4 0 4 1 00 7
Claims Expense			\$	14,061,237	\$	14,061,237
Claims IBNR			\$	-	\$	-
Medical Admin Fee	es		\$	1,364,163	\$	1,364,163
Refunds			\$	2,805	\$	2,805
Behavioral Health			\$	622,250	\$	622,250
Pharmacy Expense	es:					
RX Claims			\$	4,461,874	\$	4,461,874
RX IBNR			\$	-	\$	-
RX Admin			\$	64,477	\$	64,477
Plan Administration			\$	293,824	\$	293,824
Total Expenses	ı		\$	20,870,630	\$	20,870,630
Ioidi Expelises			Ψ	20,070,030	ψ	20,070,030
Net Income/(Loss)			\$	5,094,815	\$	5,094,815
Reserve Activity:						
_	ive Premiums for Plan Yr	10/01/10 12/21/11	¢	789,333	đ	789,333
			\$		\$	
	for Plan Year 01/01/10-	12/31/10	\$	383,402	\$	3,834,019
Net Income/(Loss)	Affer Reserves		\$	6,267,550	\$	9,718,168
Balance Sheet as	s of 10/31/10					
<u>Assets</u>						
Bank Account					\$	16,664,535
State Treasury					\$	57,737,499
Receivable from Pr	rovider				\$	513,316
Accounts Receival					\$	397,201
Due from ASE	0.0				\$	-
Total Assets					\$	75,312,551
Ioidi Asseis					φ	73,312,331
<u>Liabilities</u>						
Accounts Payable					\$	4,306
Due to ASE					\$	-
Deferred Revenues	S				\$	1,450,543
Health IBNR					\$	25,500,000
RX IBNR						2,340,000
Total Liabilities					<u>\$</u> \$	29,294,848
Net Assets					\$	46,017,703
Less Reserves Alloc	ated:					
		12/31/10 (\$4,000,000 + \$60	0.823 = \$4 600	).823)	\$	(766,804)
	for Plan Year 10/01/10-1		-,υ=υ ψ1,000	, , , , ,	\$	(11,050,667)
	for Plan Year 01/01/11-				\$ \$	(760,000)
			04 000 - ¢10 4	40 0001		, ,
		2/31/13 (\$7,344,000 + \$3,29			\$	(10,640,000)
		-12/31/13 (\$456,000 + \$304	,000 = \$/60,00	JU)	\$	(760,000)
Catastrophic Rese					\$	(9,100,000)
	d Program (2010-\$1,500	,000)			\$	(1,500,000)
Net Assets Availab	le				\$	11,440,232

Arkansas State E	mployees (ASE) Financial				30, :	2010
	ARHealth	Health Adv	No	vaSys		Total
Actives		25,093		1,215		26,30
Actives HD				958		95
Retirees	8,906					8,90
COBRA		126		8		13
otal	8,906	25,219		2,181		36,30
Operations as of 11/30/10						
				Current		Year to Date
<u>unding</u>				Month		(11 months)
tate Contribution			\$	13,647,178	\$	149,768,78
mployee Contribution, Rebo	ates, Medicare Subsidy, and	I ERRP	\$	8,153,197	\$	90,533,93
Total Funding			\$	21,800,375	\$	240,302,7
<u>xpenses</u>						
Medical Expenses						
•			Φ.	10 400 000	φ	14/1055
Claims Expense			\$	13,493,380	\$	146,195,5
Claims IBNR			\$	-	\$	2,570,0
Medical Admin Fees Defunds			\$	919,235 787	\$	9,751,3
ehavioral Health			\$	/8/	\$	19,3 2,842,3
			\$	70 100	\$	
ife Insurance			\$	79,193	\$	873,1
harmacy Expenses			•	5 105 555	<b>.</b>	50 500 0
RX Claims			\$	5,185,555	\$	53,538,2
RX IBNR			\$	-	\$	180,0
RX Admin			\$	72,412	\$	750,5
Plan Administration			\$	188,139	\$	2,347,5
Total Expenses			\$	19,938,701	\$	219,068,0
let Income/(Loss)			\$	1,861,674	\$	21,234,6
der income/(Loss)			Ψ	1,001,074	φ	21,234,0
alance Sheet as of 11/30	/10					
<u> Assets</u>						
Sank Account					\$	7,670,2
tate Treasury					\$	92,288,7
eceivable from Cafeteria P	lan				\$	8,767,6
eceivable from PSE					\$	-
eceivable from Provider					\$	539,7
Accounts Receivable					\$	1,725,0
Total Assets				-	\$	110,991,4
				=		
<u>iabilities</u>						
Accounts Payable					\$	105,1
Deferred Revenues					\$	4,169,6
Due to Cafeteria					\$	-
					\$	-
					Φ	21,570,0
lealth IBNR					\$	
lealth IBNR XX IBNR				<u>-</u>	\$	2,680,0
Due to PSE Health IBNR RX IBNR <b>Total Liabilities</b>				- -		2,680,0 28,524,7
lealth IBNR X IBNR <b>Total Liabilities</b>				-	\$	2,680,0
lealth IBNR EX IBNR Total Liabilities let Assets				:	\$	2,680,0 28,524,7
lealth IBNR EX IBNR Total Liabilities  Let Assets  ess Reserves Allocated:				-	\$	2,680,0 28,524,7 82,466,6
lealth IBNR XX IBNR	(2010. \$1.500.000)			-	\$	2,680,0 28,524,7

ASE Cafeteria Plan Financials 2010- January 1, 2	2010 through	Novembe	r 30, 2010
Cafeteria Plan Operations as of 11/30/10			
<u>Funding</u>		Current Month	Year to Date (11 months)
FICA Savings Interest, Penalties, Tax Set Off <b>Total Funding</b>	\$ \$ \$	352,659 526 353,185	\$ 3,919,166 \$ 78,981 \$ 3,998,147
<u>Expenses</u>			
Plan Administration Forfeited Benefits (Annual Expense) FICA Savings Transfer (Annual Expense)  Total Expenses	\$ \$ \$	859 - - 859	\$ 141,046 \$ 6,297,637 \$ - \$ 6,438,683
Net Income/(Loss)	\$	352,326	\$ (2,440,536)
Balance Sheet as of 11/30/10			
Assets State Cafeteria (Flexible Benefits) Admin Acct (FICA Savings) State Treasury Due from Health Plan Due from State Employee Fund Accounts Receivable Total Assets			\$ 960,644 \$ 63,122 \$ 9,933,746 \$ - \$ - \$ 13,147 \$ 10,970,658
Liabilities Accounts Payable Due to Health Plan (FICA Savings Annual) Due to Health Plan (Forfeited Benefits Annual) Total Liabilities Net Assets			\$ 331,953 \$ 28 \$ 8,767,649 \$ 9,099,631 \$ 1,871,028

Public Sc	hool Employees (PSI	) Financials - October	1, <b>2010 thro</b> u	ıgh Novemb	er 3	30, 2010
	ARHealth	Health Adv	Nov	aSys .		Total
Actives		37,469		4,605		42,074
Actives HD				2,966		2,966
Retirees	7,689					7,689
COBRA		1,126		123		1,249
Total	7,689	38,595		7,694		53,978
Operations as of		2.722				
operations as or	11/00/10			Current		Year to Date
Euro alim au				Month		(2 months)
<u>Funding</u> District Contribution			Φ.		ıτ	• •
			\$	5,901,550	\$	11,790,786
	tion, Rebates, and ERR	۲	\$	13,250,943	\$	26,395,334
Dept of Ed \$35,000,	000 & \$15,000,000		\$	3,181,818	\$	10,113,636
Total Funding			\$	22,334,311	\$	48,299,756
<u>Expenses</u>						
Medical Expenses:						
Claims Expense			4	14,938,308	¢	28,999,545
Claims IBNR			\$	14,730,300	\$	20,777,343
Medical Admin Fee			\$	1 201 100	\$	- 0.745.245
	35		\$	1,381,182	\$	2,745,345
Refunds			\$	(382)		2,423
Behavioral Health			\$	-	\$	622,250
Pharmacy Expense	S:				_	
RX Claims			\$	4,454,781	\$	8,916,656
RX IBNR			\$	=	\$	=
RX Admin			\$	66,213	\$	130,690
Plan Administration			\$	237,326	\$	531,150
Total Expenses			\$	21,077,429	\$	41,948,060
Net Income/(Loss)			\$	1,256,881	\$	6,351,697
	ve Premiums for Plan Yr for Plan Year 01/01/10- <b>After Reserves</b>		\$ \$	789,333 383,402 2,429,617	\$ \$	1,578,667 4,217,421 12,147,784
Balance Sheet as	of 11/30/10		_			
<u>Assets</u>						
Bank Account					\$	10,965,806
State Treasury					\$	64,741,078
Receivable from Pro	ovider				\$	513,316
Accounts Receivab					\$	612,382
Due from ASE	710				\$	-
Total Assets					\$	76,832,582
					Ψ	7 0,002,002
<u>Liabilities</u>						
Accounts Payable					\$	289,270
Due to ASE					\$	-
Deferred Revenues					\$	1,428,728
Health IBNR					\$	25,500,000
RX IBNR					\$	2,340,000
Total Liabilities					\$	29,557,998
Net Assets					\$	47,274,584
Loss Dosenics Alls -	ato di					
Less Reserves Alloc		10/21/10 (#4.000.000 + #40	0 000 - 04 700	1 0021	ď	1202 4001
		12/31/10 (\$4,000,000 + \$60	u,o∠s = \$4,6Ul	1,023)	\$	(383,402)
	or Plan Year 10/01/10-1				\$	(10,261,333)
	for Plan Year 01/01/11-			10.0051	\$	(760,000)
		2/31/13 (\$7,344,000 + \$3,29			\$	(10,640,000)
		-12/31/13 (\$456,000 + \$304	0.000 = \$760.00	00)	\$	(760,000)
Catastrophic Rese					\$	(9,100,000)
	d Program (2010-\$1,500)	.000)			\$	(1,500,000)
Net Assets Availabl	е				\$	13,869,849

Arkunsas state E	mployees (ASE) Financial				<b>υ</b> Ι, .	
A 12	ARHealth	Health Adv	No	vaSys		Total
Actives		25,162		1,206		26,36
Actives HD	0.007			977		97
Retirees	8,926	114		7		8,92
COBRA	0.007	114		7		12
otal	8,926	25,276		2,190		36,39
Operations as of 12/31/10						
				Current		Year to Date
<u>unding</u>				Month		(12 months)
tate Contribution			\$	13,645,338	\$	163,414,12
	ates, Medicare Subsidy, and	ERRP	\$	8,359,032	\$	98,892,96
Total Funding			\$	22,004,370	\$	262,307,08
<u>xpenses</u>						
Medical Expenses						
Claims Expense			\$	13,315,784	\$	159,511,30
Claims IBNR			\$ \$	10,010,704	₽ \$	2,570,00
Medical Admin Fees			\$	- 882,176	\$ \$	10,633,56
defunds			Ψ \$	3,077		22,37
ehavioral Health			\$ \$	567,390	\$ \$	3,409,73
ife Insurance			\$	101,884	\$ \$	974,99
			Ф	101,004	Ф	9/4,97
harmacy Expenses			¢	E 210 1E4	ď	E0.0E/ //
RX Claims			\$	5,318,154	\$	58,856,43
RX IBNR			\$	70.450	\$	180,00
RX Admin			\$ \$	72,458	\$	823,00
Plan Administration			\$	217,888	\$	2,565,43
Total Expenses			<u> </u>	20,478,812	\$	239,546,84
let Income/(Loss)			\$	1,525,557	\$	22,760,23
ver meome/(1033)			Ψ	1,020,007	Ψ	22,7 00,20
Balance Sheet as of 12/31	/10					
<u> Assets</u>						
Bank Account					\$	10,381,30
State Treasury					\$	92,296,63
Receivable from Cafeteria P	lan				\$	8,767,64
Receivable from PSE					\$	-
Receivable from Provider					\$	507,08
Accounts Receivable					\$	821,12
Total Assets					\$	112,773,80
<u>iabilities</u>						
Accounts Payable					\$	1,26
Deferred Revenues					\$	4,275,67
Due to Cafeteria					\$	9
Due to PSE					\$	254,52
lealth IBNR					\$	21,570,00
RX IBNR					\$	2,680,00
Total Liabilities					\$	28,781,56
Net Assets					\$	83,992,24
						. ,
ess Reserves Allocated:						
Catastrophic Reserve					\$	(8,100,00
Pharmacy Reward Program  Net Assets Available	n (2010-\$1,500,000)				<u>\$</u> \$	(1,500,00 74,392,24

ASE Cafeteria Plan Financials 2010- January 1, 2010 through December 31, 2010						
Cafeteria Plan Operations as of 12/31/10						
<u>Funding</u>	_	Current Month	Year to Date (12 months)			
FICA Savings Interest, Penalties, Tax Set Off <b>Total Funding</b>	\$ \$	383,600 1,167 384,767	\$ 4,302,766 \$ 80,148 \$ 4,382,914			
<u>Expenses</u>						
Plan Administration Forfeited Benefits (Annual Expense) FICA Savings Transfer (Annual Expense)  Total Expenses	\$ \$ \$	26,657 - - 26,657	\$ 167,702 \$ 6,297,637 \$ - \$ 6,465,340			
Net Income/(Loss)	\$	358,110	\$ (2,082,426)			
Balance Sheet as of 12/31/10						
Assets State Cafeteria (Flexible Benefits) Admin Acct (FICA Savings) State Treasury Due from Health Plan Due from State Employee Fund Accounts Receivable Total Assets			\$ 1,148,152 \$ 422,882 \$ 9,934,588 \$ 98 \$ - \$ 11,046 \$ 11,516,766			
<u>Liabilities</u> Accounts Payable Due to Health Plan (FICA Savings Annual) Due to Health Plan (Forfeited Benefits Annual)  Total Liabilities			\$ 519,979 \$ - \$ 8,767,649 \$ 9,287,628			
Net Assets			\$ 2,229,138			

Public Sc	1, 2010 through December 31, 2010					
	ARHealth	Health Adv	Nov	aSys		Total
Actives		37,513		2,959		40,472
Actives HD				4,651		4,651
Retirees	7,699					7,699
COBRA		1,099		123		1,222
Total	7,699	38,612		7,733		54,044
Operations as of						
operations as or	12/01/10			Current		Year to Date
Eundina				Month		(3 months)
Funding District Contribution	_		<u></u>		Φ.	• •
			\$ \$	5,912,554 13,512,119	\$	17,703,340
Employee Contribu	\$	39,907,452				
Dept of Ed \$35,000,	,000 & \$15,000,000		<u>\$</u>	3,181,818	\$	13,295,455
Total Funding			<u> </u>	22,606,491	\$	70,906,247
<u>Expenses</u>						
Medical Expenses:						
Claims Expense			•	16,960,310	¢	45,959,855
Claims IBNR			\$	10,700,310	\$	43,737,033
			\$	1 241 107	\$	4.007.543
Medical Admin Fee	<del>S</del> S		\$	1,341,197	\$	4,086,543
Refunds			\$	4,886	\$	7,309
Behavioral Health			\$	642,016	\$	1,264,267
Pharmacy Expense	es:					
RX Claims			\$	4,483,079	\$	13,399,735
RX IBNR			\$	-	\$	-
RX Admin			\$	66,040	\$	196,730
Plan Administration	l		\$	293,156	\$	824,307
Total Expenses			\$	23,790,685	\$	65,738,745
Net Income/(Loss)			\$	(1,184,194)	\$	5,167,502
Reserve Activity:           Allocation for Active Premiums for Plan Yr 10/01/10-12/31/11         \$ 789,333           Retiree Premiums for Plan Year 01/01/10-12/31/10         \$ 383,402					\$ \$	2,368,000 4,600,823
Net Income/(Loss)		12,01,10	\$	(11,459)	\$	12,136,325
` '			<u> </u>	(117107)	Ψ	12,100,020
Balance Sheet as Assets	s of 12/31/10					
Bank Account					\$	9,507,906
State Treasury					\$	64,746,335
Receivable from Pr	rovidor				-	
Accounts Receivab					\$	471,138 277,932
	JIE				φ	
Due from ASE  Total Assets					\$	254,522
ioidi Asseis					\$	75,257,834
<u>Liabilities</u> Accounts Payable					4	4 2 4 4
Due to ASE					\$	4,264
					\$	1 202 100
Deferred Revenues	5				\$	1,323,180
Health IBNR					\$	25,500,000
RX IBNR					\$ \$	2,340,000
Total Liabilities					\$	29,167,444
Net Assets					\$	46,090,390
Less Reserves Alloc						_
		12/31/10 (\$4,000,000 + \$60	0,823 = \$4,600	,823)	\$ \$	0
Active Premiums for Plan Year 10/01/10-12/31/11 (\$11,840,000)						(9,472,000)
Retiree Premiums for Plan Year 01/01/11-12/31/11 (\$760,000)						(760,000)
Active Premiums fo	or Plan Years 1/01/12-1:	2/31/13 (\$7,344,000 + \$3,29	96,000 = \$10,6	40,000)	\$ \$	(10,640,000)
		12/31/13 (\$456,000 + \$304			\$	(760,000)
Catastrophic Rese					\$	(9,100,000)
· ·	d Program (2010-\$1,500)	.000)			\$	(1,500,000)
Net Assets Availabl		•			\$	13,858,390
					_	

### The Drug Utilization and Evaluation Committee (DUEC)

The following recommendations for the Board consideration resulted from a meeting of the DUEC on February 7, 2011.

**1. MAXALT -** Generic Name: rizatriptan (RYE za TRIP tan)

Maxalt is used to treat migraine headaches.

Maxalt packaging has changed from 12 tablets to 18 tablets per package.

Current Policy: 12 tablets per 31 days

**Recommendation** – Allow for 18 tablets per 45 days.

The committee agreed to allow EBD to manage the prescription and co-pay adjustments and to inform the committee if needed.

#### 2. FIRST REVIEW MEDICATIONS – NEW DRUGS Oct-Dec 2010

<u>Drug Name</u> <u>Tier Status</u>

GILENYA CAP 0.5MG T3 w PA. Specialty

GILENYA (fingolimod) is the first oral therapy approved for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

PRADAXA CAP 75, 150MG T3 w/ PA QL/2tab a day per 31 days

PRADAXA is FDA-approved for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

Jill T. Johnson, Pharm.D., BCPS Associate Professor, UAMS College of Pharmacy February 7, 2011

# Review of Newer Diabetes Drugs for Type 2 Diabetes Mellitus

1

# 2010 EBD-by Plan Paid (po drugs only)

Product Name	Plan Cost Paid		
	Amount	011/01/01/05	445.005.00
		<u>GLYBURIDE</u>	\$15,087.88
		<u>GLUMETZA</u>	\$12,797.53
<u>ACTOS</u>	\$2,336,900.26	<u>ACARBOSE</u>	\$13,608.55
<u>JANUVIA</u>	\$603,308.54	<u>GLIPIZIDE</u>	\$1,720.11
ACTOPLUS MET	\$484,448.50	<u>STARLIX</u>	\$7,253.36
<u>JANUMET</u>	\$345,818.53	<u>GLUCOVANCE</u>	\$4,430.47
<u>METFORMIN HCL</u>	\$112,556.54	<u>GLYSET</u>	\$5,399.27
GLYBURIDE/METFORMIN HCL	\$140,915.51	ACTOPLUS MET XR	\$6,412.34
ONGLYZA	\$102,631.78	GLUCOPHAGE XR	\$2,039.45
AVANDIA	\$96,569.83	<u>FORTAMET</u>	\$562.44
PRANDIN	\$98,870.28	GLUCOTROL XL	\$526.58
AVANDAMET	\$65,420.78	<u>GLUCOPHAGE</u>	\$2,050.63
GLIPIZIDE ER	\$53,848.98	GLYBURIDE MICRONIZED	\$1,994.51
DUETACT	\$58,679.70	AMARYL	\$196.93
GLIMEPIRIDE	\$33,582.05	<u>GLUCOTROL</u>	\$169.53
METFORMIN HCL ER	\$31,958.80	GLYNASE	\$42.12
		<u>RIOMET</u>	\$170.98
<u>NATEGLINIDE</u>	\$51,429.11	<u>TOLBUTAMIDE</u>	\$216.75
<u>AVANDARYL</u>	\$29,392.43	<u>METAGLIP</u>	\$51.63
GLIPIZIDE/METFORMIN HCL	\$31,502.97	CHLORPROPAMIDE	\$100.75
GLIPIZIDE XL	\$23,565.96	<u>PRECOSE</u>	\$0.00

# 2010 EBD-by Utilizing Members (podrugs only)

Product Name	Utilizing Members	<u>ACARBOSE</u>	62
	iviembers	GLIPIZIDE/METFORMIN	58
METFORMIN HCL	5,452	<u>HCL</u> DUETACT	36
ACTOS	1,556	AVANDARYL	30
<u> </u>	·	<u>GLUMETZA</u>	29
METFORMIN HCL ER	1,446	<u>STARLIX</u>	18
<u>GLIMEPIRIDE</u>	1,356	GLUCOVANCE	13
GLYBURIDE/METFORMIN	847	<u>GLYSET</u>	12
<u>HCL</u>	847	<u>GLUCOTROL XL</u>	12
<u>GLIPIZIDE</u>	784	GLUCOPHAGE XR	10
GLIPIZIDE ER	686		
<u>JANUVIA</u>	605	ACTOPLUS MET XR	9
<u>GLYBURIDE</u>	574	FORTAMET	7
<u>JANUMET</u>	385	AMARYL	7
ACTOPLUS MET	352	GLUCOPHAGE	5
GLIPIZIDE XL	332		2
<u>ONGLYZA</u>	173	<u>CHLORPROPAMIDE</u>	2
<u>AVANDIA</u>	141	<u>GLUCOTROL</u>	1
<u>PRANDIN</u>	87	<u>GLYNASE</u>	1
<u>AVANDAMET</u>	73	<u>RIOMET</u>	1
GLYBURIDE MICRONIZED	72	<u>TOLBUTAMIDE</u> METAGLIP	1 1
NATEGLINIDE	67	PRECOSE	1 3

# TZDs (rosiglitazone, pioglitazone), (Avandia, Avandaryl, Avandamet, Actos, ActoplusMet)

#### **CURRENT**

#### • No edits for EBD members

#### **PROPOSED**

- Restrict the access to rosiglitazone. Stop covering rosiglitazone (Avandia, Avandamet, Avandaryl) effective July 1, 2011.
- No pioglitazone (Actos)
   without metformin (at a near
   maximum daily dose-1000mg
   daily) or a contraindication to
   metformin.

4

# Exenatide (Byetta) Liraglutide (Victoza)

#### **CURRENT**

- No monotherapy allowed
- 120 day lookback for 1 fill of metformin, sulfonylurea, or TZD.

#### **PROPOSED**

- Option 1.
  - Discontinue covering these drugs based on lack of outcomes evidence.
- Option 2.
  - Deny if any insulin claim in past 3od.
  - Continue no monotherapy access for exenatide or liraglutide.
  - PA all prescriptions, criteria:
    - require a current metformin fill for 90 of the past 120 days at the maximum or near-maximum dose, failure to reach goal A1C, AND then
    - Require, in patients who cannot tolerate metformin, the use of a sulfonylurea or the use of pioglitazone, unless contraindicated due to HF, edema, or fracture risk.
- If renal function will not allow metformin (CrCl <3omL/min), then should not take exenatide either; For Victoza, use with caution with renal impairment, limited experience.

5

# Sitagliptin (Januvia, Janumet) Saxagliptin (Onglyza, Kombiglyze XR)

#### **CURRENT**

- No monotherapy allowed
- 120 day lookback for 1 fill of metformin

#### **PROPOSED**

- Option 1.
  - Discontinue covering these drugs based on lack of outcomes evidence.
- Option 2
  - \*\*\*Deny if any insulin claim in past 3od.
  - Continue no monotherapy access for sitagliptin or saxagliptin.
  - PA all prescriptions, criteria:
    - Require a current metformin fill for 90 of the past 120 days at the maximum or near-maximum dose failure to reach goal A1C, AND
    - Require the use of concomitant sulfonylurea &/or pioglitazone in patients who have not reached their HbA1C goal with metformin monotherapy, unless contraindicated due to HF, edema, or fracture risk.

\*\*\*Sitagliptin has the FDA approval to be given with insulin for T2DM. There is no evidence regarding whether sitagliptin with or without insulin results in improved health outcomes. In the company-sponsored trial, sitagliptin + insulin + metformin was "well-tolerated". The A1C was 0.6% less in the sitagliptin group but the insulin arm was fixed.

6

# Pramlintide (Symlin, Symlinpen)

#### **CURRENT**

#### **PROPOSED**

No edits

Exclude

7

#### State and Public School Life and Health Insurance Board

### **Benefits Sub-Committee Report**

Meeting Date: January 14, 2011

#### 1. PSE 2010 PLAN YEAR REVIEW

Lee provided an overview of the 2010 PSE plan year.

The 2010 Plan Year incorporated only a few changes from 2009; hearing exams, hearing aids, and vision exams were added to the standard schedule of benefits. Enrollment remained stable with just under 75% of eligible employee selecting to join the plan. HDPPO participation increased significantly to more than 10% of the active public school employees. Claims utilization on a per contract per month basis increased above 2009 level; however pharmacy claims, mental health premiums, and administration expenses fell. Trust fund account balance is stable after reserve allocations for 2011, 2012, and 2013.

# 2. MEDICARE ADVANTAGE – POST HEALTHCARE REFORM DISCUSSION

The committee reviewed a side by side comparison of the current health plan arrangement for ARHealth active employees and Medicare primary members vs. the Medicare Advantage plan.

The committee discussed Medicare Advantage as a possible option for the ARHealth Medicare Retiree population.

The committee requested further in depth investigation by the BSPW in conjunction with our actuarial firm to look into financial data on what we are doing compared to Medicare Advantage Plan without restriction and evaluate the same advantages of a employer group waiver plan.

### 2010 PSE - Plan Year Review

The 2010 Plan Year incorporated only a few changes from 2009; hearing exams, hearing aids, and vision exams were added to the standard schedule of benefits. Enrollment remained stable with just under 75% of eligible employees electing to join the plan. HD PPO participation increased significantly to more than 10% of the active public school employees. Claims utilization on a per contract per month basis increased above 2009 level however pharmacy claims, mental health premiums, and administration expenses fell. Trust fund account balance is stable after reserve allocations for 2011, 2012, and 2013

		Total		r Contract Per lonth (PCPM)	Pe	ercent of Total Spend	Percent of Enrollment	Jan-10	Oct-10
Medical Claims Expense	\$1	92,676,020.00	\$308.77			73%	ARHealth	94.40%	% 89.90%
Pharmacy Claims Expense	\$	\$49,683,757.00		\$79.62		19%	ARHealth HD PPC	D 5.60%	% 10.10%
Behavioral Health Expense	\$3,411,508.00		\$5.47		1%				
Administration Expense	\$	319,682,587.00		\$31.54	7%		2010 Contract Months		624,005
	Total * \$2	265,453,872.00							
		2007		2008		2009	2010		
Medical Claims - PCPM	\$	279.94	\$	284.82	\$	298.97	\$308.	.77	
Pharmacy Claims - PCPM	\$	81.18	\$	77.85	\$	81.78	\$79.	.62	
Behavioral Health - PCPM	\$	5.32	\$	6.14	\$	6.02	\$5.	.47	
Administration - PCPM	\$	36.67	\$	30.10	\$	33.68	\$31.	<u>.54</u>	
	\$	403.11	\$	398.91	\$	420.45	\$ 425.4	40	
		2007		2008		2009	2010		
Medical Claims - PCPM		69%		71%		71%	73	3%	
Pharmacy Claims - PCPM	20%		20%		19%		19	9%	
Behavioral Health - PCPM		1%		2%		1%	,	1%	
Administration - PCPM		9%		8%		8%	, 7	7%	

<sup>\*</sup> Actual financial statement reflects IBNR and Refunds not reflected here
Information taken from September 2010 financial report and ARBenefits.org enrollment data
Contract defined as primary employee member or retiree member - count does not include dependents